Urinary DNA Methylation Biomarkers for Noninvasive Prediction of Aggressive Disease in Patients with Prostate Cancer on Active Surveillance

Genitourinary Cancer

Tailoring Intensity of Active Surveillance for Low-Risk Prostate Cancer Based on Individualized Prediction of Risk Stability

JAMA Oncol.

Cooperberg MR, Zheng Y, Faino AV, Newcomb LF, Zhu K, Cowan JE, Brooks JD, Dash A, Gleave ME, Martin F, Morgan TM, Nelson PS, Thompson IM, Wagner AA, Carroll PR, Lin DW

doi: 10.1001/jamaoncol.2020.3187.

Genitourinary Cancer

Germline sequencing DNA repair genes in 5,545 men with aggressive and non-aggressive prostate cancer

J Natl Cancer Inst.

Darst BF, Dadaev T, Saunders E, Sheng X, Wan P, Pooler L, Xia LY, Chanock S, Berndt SI, Gapstur SM, Stevens V, Albanes D, Weinstein SJ, Gnanapragasam V, Giles GG, Nguyen-Dumont T, Milne RL, Pomerantz M, Schmidt JA, Mucci L, Catalona WJ, Hetrick KN, Doheny KF, MacInnis RJ, Southey MC, Eeles RA, Wiklund F, Kote-Jarai Z, Conti DV, Haiman CA

doi: 10.1093/jnci/djaa132.

Genitourinary Cancer

Patient-Reported Outcomes Through 5 Years for Active Surveillance, Surgery, Brachytherapy, or External Beam Radiation With or Without Androgen Deprivation Therapy for Localized Prostate Cancer

JAMA.

Hoffman KE, Penson DF, Zhao Z, Huang LC, Conwill R, Laviana AA, Joyce DD, Luckenbaugh AN, Goodman M, Hamilton AS, Wu XC, Paddock LE, Stroup A, Cooperberg MR, Hashibe M, O'Neil BB, Kaplan SH, Greenfield S, Koyama T, Barocas DA

doi: 10.1001/jama.2019.20675.

Genitourinary Cancer

Incorporating MRI and biomarkers in active surveillance protocols - results from the prospective Stockholm3 Active Surveillance trial (STHLM3AS)

J Natl Cancer Inst.

Olsson H, Nordström T, Jäderling F, Egevad L, Vigneswaran HT, Annerstedt M, Grönberg H, Eklund M, Lantz A

doi: 10.1093/jnci/djaa131.

Lung, Respiratory and Thoracic Cancer

Epigenomic profiling of non-small cell lung cancer xenografts uncover LRP12 DNA methylation as predictive biomarker for carboplatin resistance

Genome Med.

Grasse S, Lienhard M, Frese S, Kerick M, Steinbach A, Grimm C, Hussong M, Rolff J, Becker M, Dreher F, Schirmer U, Boerno S, Ramisch A, Leschber G, Timmermann B, Grohé C, Lüders H, Vingron M, Fichtner I, Klein S, Odenthal M, Büttner R, Lehrach H, Sültmann H, Herwig R, Schweiger MR

doi: 10.1186/s13073-018-0562-1.

Genitourinary CancerRadio-Oncology

Association Between Choice of Radical Prostatectomy, External Beam Radiotherapy, Brachytherapy, or Active Surveillance and Patient-Reported Quality of Life Among Men With Localized Prostate Cancer

JAMA.

Chen RC, Basak R, Meyer AM, Kuo TM, Carpenter WR, Agans RP, Broughman JR, Reeve BB, Nielsen ME, Usinger DS, Spearman KC, Walden S, Kaleel D, Anderson M, Stürmer T, Godley PA

doi: 10.1001/jama.2017.1652.

Genitourinary Cancer

Magnetic Resonance Imaging-Transrectal Ultrasound Guided Fusion Biopsy to Detect Progression in Patients with Existing Lesions on Active Surveillance for Low and Intermediate Risk Prostate Cancer

J Urol.

Frye TP, George AK, Kilchevsky A, Maruf M, Siddiqui MM, Kongnyuy M, Muthigi A, Han H, Parnes HL, Merino M, Choyke PL, Turkbey B, Wood B, Pinto PA

doi: 10.1016/j.juro.2016.08.109.

Genitourinary Cancer

Association Between Combined TMPRSS2:ERG and PCA3 RNA Urinary Testing and Detection of Aggressive Prostate Cancer

JAMA Oncol.

Sanda MG, Feng Z, Howard DH, Tomlins SA, Sokoll LJ, Chan DW, Regan MM, Groskopf J, Chipman J, Patil DH, Salami SS, Scherr DS, Kagan J, Srivastava S, Thompson IM Jr, Siddiqui J, Fan J, Joon AY, Bantis LE, Rubin MA, Chinnayian AM, Wei JT; and the EDRN-PCA Study Group, Bidair M, Kibel A, Lin DW, Lotan Y, Partin A, Taneja S

doi: 10.1001/

SARS-CoV-2 infection in cancer patients undergoing active treatment: analysis of clinical features and predictive factors for severe respiratory failure and death

Eur J Cancer.

Yarza R, Bover M, Paredes D, López-López F, Jara-Casas D, Castelo-Loureiro A, Baena J, Mazarico JM, Folgueira MD, Meléndez-Carmona MÁ, Reyes A, Lumbreras C, Paz-Ares L, Díaz-Pedroche C, Gómez-Martín C

doi: 10.1016/j.ejca.2020.06.001.

Related content

Tailoring Intensity of Active Surveillance for Low-Risk Prostate Cancer Based on Individualized Prediction of Risk Stability

Germline sequencing DNA repair genes in 5,545 men with aggressive and non-aggressive prostate cancer

Patient-Reported Outcomes Through 5 Years for Active Surveillance, Surgery, Brachytherapy, or External Beam Radiation With or Without Androgen Deprivation Therapy for Localized Prostate Cancer

Incorporating MRI and biomarkers in active surveillance protocols - results from the prospective Stockholm3 Active Surveillance trial (STHLM3AS)

Epigenomic profiling of non-small cell lung cancer xenografts uncover LRP12 DNA methylation as predictive biomarker for carboplatin resistance

Association Between Choice of Radical Prostatectomy, External Beam Radiotherapy, Brachytherapy, or Active Surveillance and Patient-Reported Quality of Life Among Men With Localized Prostate Cancer

Magnetic Resonance Imaging-Transrectal Ultrasound Guided Fusion Biopsy to Detect Progression in Patients with Existing Lesions on Active Surveillance for Low and Intermediate Risk Prostate Cancer

Association Between Combined TMPRSS2:ERG and PCA3 RNA Urinary Testing and Detection of Aggressive Prostate Cancer

SARS-CoV-2 infection in cancer patients undergoing active treatment: analysis of clinical features and predictive factors for severe respiratory failure and death